Currently, the FGFR inhibitor Erdafinib is FDA-approved for advanced or metastatic BLCA patients with FGFR3 or FGFR2 mutations who have progressed in platinum-containing chemotherapy [50]. The gene discussed is FGFR2; the disease is bladder transitional cell carcinoma.